ArticlesCelecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
Introduction
Present approaches to reduce risk of upper gastrointestinal adverse events associated with non-steroidal anti-inflammatory drugs (NSAIDs) recommend use of a non-selective NSAID plus a proton-pump inhibitor (PPI) or a cyclo-oxygenase (COX)-2 selective NSAID alone.1, 2, 3 Although these guidelines, which are based on previous work by ourselves and others,4, 5, 6, 7 suggest that both strategies reduce risk to the upper gastrointestinal tract, they do not address gastrointestinal adverse events originating beyond the duodenum. Although NSAID use is associated with injury to the small bowel and colon,4, 8, 9, 10 leading to overt bleeding, ulceration, occult blood loss, or development of anaemia, evidence suggests that COX-2 selective NSAIDs are associated with fewer mucosal lesions of the small bowel than are non-selective NSAIDs plus a PPI.11, 12 Prespecified prospective trials directly comparing clinically relevant sequelae of these strategies throughout the gastrointestinal tract are not available.
To address the absence of a comprehensive yet clinically practical endpoint, we proposed a composite endpoint of clinically significant events throughout the gastrointestinal tract (referred to in the protocol as clinically significant upper or lower gastrointestinal events) as a common platform for comparison of future clinical trials of gastrointestinal safety.13 This endpoint was designed to assess several potential outcomes relevant to clinical practice, ranging from discontinuation of treatment due to presumed significant occult blood loss to admission to hospital for life-threatening complications. We also included presumed significant occult gastrointestinal blood loss in the definition of the endpoint because this outcome is relevant in view of the number of patients at risk and the potential downstream clinical implications and economic effect.
Since damage to the small bowel and colon is not acid-dependent,14, 15 we postulated that the risk of clinical outcomes across the entire gastrointestinal tract associated with celecoxib would be lower than that associated with diclofenac plus omeprazole. To address this hypothesis, we aimed to compare treatment with celecoxib and diclofenac plus omeprazole in patients with osteoarthritis and rheumatoid arthritis at increased gastrointestinal risk.
Section snippets
Study design and patients
We undertook a double-blind, triple-dummy, parallel-group randomised trial at 196 active (having recruited more than one patient) centres in 32 countries or territories. One site was excluded because it did not comply with International Conference on Harmonisation Good Clinical Practice guidelines. The protocol was approved by local institutional review boards; all participants provided written informed consent.
Patients with a clinical diagnosis of osteoarthritis or rheumatoid arthritis were
Results
Between Oct 31, 2005, and May 11, 2009, 8098 potentially eligible patients were screened; 4484 patients were enrolled and were included in intention-to-treat analyses (2238 celecoxib, 2246 diclofenac plus omeprazole; figure 1, table 1). Predominant reasons for screening failure were H pylori infection (2476 patients, 75%) and low baseline haemoglobin (217, 6%). 876 patients initially infected with H pylori were successfully treated and then randomly allocated to celecoxib (444, 51%) and
Discussion
In this population of patients with osteoarthritis or rheumatoid arthritis who were not using antiplatelet and anticoagulant drugs, the rate of clinically significant gastrointestinal events was four times higher in those receiving diclofenac plus omeprazole than in those receiving celecoxib. As in our previous trial, rates of upper gastrointestinal bleeding did not differ between treatment groups.4 However, we noted large differences for the likelihood of clinically significant blood loss from
References (31)
- et al.
Summing the risk of NSAID therapy
Lancet
(2007) - et al.
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines
Osteoarthritis Cartilage
(2008) - et al.
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications
Am J Med
(2005) - et al.
Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs
Gastroenterology
(2007) - et al.
Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease
Gastroenterology
(1983) - et al.
Visible small-intestinal mucosal injury in chronic NSAID users
Clin Gastroenterol Hepatol
(2005) - et al.
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo
Clin Gastroenterol Hepatol
(2005) - et al.
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomised double-blind trial
Gastroenterology
(2004) - et al.
Comparing rates of dyspepsia with coxibs vs NSAID+PPI: a meta-analysis
Am J Med
(2006) - et al.
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
Am J Med
(2006)